Phase 1 Deltacel-01 Interim Results
With an eye toward assessing DeltacelTM (KB-GDT-01) in patients with stage 4 metastatic non-small cell lung cancer (NSCLC), Kiromic BioPharma, Inc. (OTCQB: KRBP) has provided interim results from Part 1 of the Deltacel-01 Phase 1 clinical trial. Five patients who have received treatment are part of this trial meant to evaluate Progression-Free Survival (PFS). With an average of 4.8 months, the PFS results among these patients range from 2 to 8 months. Especially, no dose-limiting toxicities (DLTs) have been documented for any patient who followed their treatment course exactly. One patient, however, was not evaluated for PFS and withdrew from the study because of an adverse event connected to a pre-existing condition. Completing enrollment for this phase, the last patient in Part 1 commenced treatment on August 6th. Completing Part 1 represents a major turning point that will open the path for Part 2 to start. Kiromic still sees great hope for DeltacelTM's ability to enhance NSCLC patients' outcomes.
Progression-Free Survival Outcomes in Part 1
With an average of 4.8 months among the first five patients, the interim findings of the Deltacel-01 trial show a spectrum of Progression-Free Survival (PFS) results. This result implies a good response in treating stage 4 NSCLC patients who have run out of conventional treatments.
Enrollment Completion and Next Steps
Part 1 of the Deltacel-01 trial is now finished with the last patient enrolled on August 6. After the first patient cohort, the trial will move to Part 2, expected to expand on the results and assess the safety and effectiveness of the therapy.
Safety Profile of Deltacel™ Therapy
Thus far, the Deltacel-01 trial shows a favorable safety profile for DeltacelTM (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy. Patients who followed the recommended course of treatment reported no dose-limiting toxicities (DLTs), so suggesting a good tolerance for the treatment. This is significant since the main goal of this Phase 1 study is safety. One patient, though, was taken off the trial before finishing treatment because of a negative event connected to a pre-existing condition. The incident had nothing bearing on DeltacelTM, which guarantees the therapy's safety itself. Although it somewhat affects the data, the withdrawn patient could not be assessed for Progression-Free Survival (PFS), which does not compromise the general positive safety findings. These results will direct the ongoing trial into Part 2, where safety will remain a top priority.
Absence of Dose Limiting Toxicities
Lack of dose-limiting toxicities (DLTs) in the Deltacel-01 trial is a favorable sign of DeltacelTM's safety. This result supports the therapeutic possibilities for additional development and application in advanced NSCLC treatment.
Pre-existing Conditions and Adverse Events
One adverse event connected to a pre-existing condition surfaced in the trial and resulted in patient withdrawal. This incident underlined the need of patient choice and monitoring in clinical studies since it had nothing to do with DeltacelTM.
Insights into Part 1 of Deltacel-01
The first part of the Deltacel-01 trial has shed important light on DeltacelTM's possibilities for treating stage 4 metastatic NSCLC. Six patients undergoing allogeneic GDT treatment along with low-dose radiation made up this component of the trial. Five patients had their Progression-Free Survival (PFS) evaluated; the outcomes ranged from two to eight months. One patient withdrew because of an unrelated adverse event, underscoring the difficulties in treating a population this sick. This first phase ends when the sixth and last patient joins Part 1. Early results, especially considering the absence of dose-limiting toxicities, point to DeltacelTM as both safe and maybe effective. These results will guide the planning and goals of Part 2, which will investigate the safety and effectiveness of the therapy more broadly. For Kiromic BioPharma and their DeltacelTM system, finishing Part 1 successfully marks a major turning point.
Patient Cohorts and Treatment Timeline
Six patients undergoing two intravenous DeltacelTM injections mixed with low-dose radiation made up the Part 1 of the Deltacel-01 trial. Patients under the treatment were watched for safety and results over a ten-day period.
Expectations for Final Safety and Efficacy Data
Kiromic anticipates reporting final safety and efficacy data for the last patient registered in Part 1 by September and October, respectively. These findings will direct the upcoming stage of the trial as well as future DeltacelTM development.
Overview of Deltacel-01 Trial Objectives
Designed as a Phase 1 study, the Deltacel-01 trial aims to assess DeltacelTM's safety and tolerability in stage 4 metastatic non-small cell lung cancer (NSCLC) patients. Two intravenous allogeneic Gamma Delta T-cell infusions plus low-dose, localized radiation form part of the trial. With an eye toward spotting any dose-limiting toxicities (DLTs) or other adverse events, this trial's main goal is to evaluate the safety of DeltacelTM. Measuring Progression-Free Survival (PFS), general survival, time to progression, and disease control rates comprise secondary goals. The design of the trial intends to compile thorough information on the possibilities of DeltacelTM to treat advanced NSCLC. The results of this trial will be absolutely vital in deciding DeltacelTM's course as a therapy choice. Kiromic BioPharma is dedicated to forward this trial to provide patients with few treatment choices fresh hope.
Primary Objective: Safety and Tolerability
Evaluating the safety and tolerability of DeltacelTM in stage 4 NSCLC patients is the main objective of the Deltacel-01 trial This covers tracking for any adverse events including dose-limiting toxicities (DLTs).
Secondary Measurements: Survival and Disease Control
Apart from safety, the trial is assessing disease control rates, general survival, and Progression-Free Survival (PFS). These secondary goals will help one to grasp the possible potency of DeltacelTM.
The Potential of Deltacel™ in Treating NSCLC
Kiromic BioPharma developed investigational Gamma Delta T-cell therapy DeltacelTM (KB-GDT-01) to treat stage 4 metastatic non-small cell lung cancer (NSCLC). Targeting solid tumors, this therapy uses the natural potency of Gamma Delta T-cells—a fresh approach in the treatment of NSCLC that fits 80% to 85% of all lung cancer cases. Being an allogeneic product, DeltacelTM uses donor-derived cells that can be produced off-the-shelf, so offering a possibly more easily available treatment choice. Particularly when coupled with low-dose radiation, preclinical studies of DeltacelTM have shown encouraging findings showing a favorable safety and efficacy profile. These results have prepared the ground for the continuing Deltacel-01 Phase 1 clinical trial. Kiromic BioPharma sees DeltacelTM's promise to provide patients with advanced NSCLC a fresh treatment path. The company is concentrated on bringing this treatment to market by means of clinical development, so advancing it.
The Role of Gamma Delta T-Cells in Solid Tumor Treatment
One special group of T-cells with natural anti-tumor qualities are gamma delta T-cells. Offering a fresh approach to NSCLC treatment, DeltacelTM targets and kills cancer cells in solid tumors by harnessing these cells.
Preclinical Studies Supporting Deltacel™’s Efficacy
Combining low-dose radiation with DeltacelTM has proven safe and efficient in targeting NSCLC according preclinical studies. These findings support the continuing clinical studies as well as the possible wider therapeutic uses.
To learn more, visit https://kiromic.com/
